Volume 3, Issue 10, 2025

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

ATRIAL AND VENTRICULAR ARRHYTHMIAS: PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL CONSEQUENCES

Shahid Mahmood[*1], Nimra Fatima[2], Eman Fatima[3], Saman Imtiaz[4], Naila Sehar[5], Haleema Sadia[6]

[*1,2,3,4,5,6]*Department of Zoology, University of Gujrat, Gujrat 50700, Pakistan*

[*1]shahid.mahmood@uog.edu.pk

DOI: https://doi.org/10.5281/zenodo.18165213

Keywords

Heart instability; atrial fibrillation, rhythm, Catheter-based ablation, COVID-19

Article History

Received: 11 October 2025
Accepted: 21 November 2025
Published: 31 December 2025

Copyright @Author

Corresponding Author: *
Shahid Mahmood

Abstract

The cardiac arrhythmia is a wide variety of conditions affecting the normal rhythm, rate, or conduction of the heart as a result of disruption to its highly controlled electrical system. The rhythmical activity of the SA node and AV node, when connected properly to the His-Purkinje system network is essential for a healthy functioning heart, and disturbances at any level can provoke pathological rhythms. Arrhythmias are further divided into supraventricular and ventricular arrhythmias with practical exposure to some common entities including atrial fibrillation, atrial flutter special consideration on the ventricular tachycardia, ventricular fibrillation, premature beats, Brady arrhythmia and above all stressing underlining causes and clinical implications of these conditions. The electrophysiological substrate for arrhythmogenesis re-entry phenomenon, abnormal automaticity and triggered activity. The role of arrhythmias as well as structural heart disease, metabolic dysfunction, myocardial infarction, emotional and lifestyle factors and systemic illnesses especially in COVID-19 is discussed to demonstrate the way in which cardiac rhythm disturbances frequently represent complex underlying pathophysiological processes. Introduction Recent developments in diagnostic methods such as electrocardiography, ambulatory monitoring, echocardiography, invasive electrophysiological studies and wearable devices have greatly influenced the process of early detection and risk stratification. Consideration is also given to the possible sequences of untreated arrhythmias and therapy-induced side-effects.

INTRODUCTION

Cardiac arrhythmias refer to a group of disorders characterized by the hearts irregular conduction of electrical signals leading to abnormal or irregular heartbeats. These rhythm disturbances range from premature beats, to life-threatening tachyarrhythmia and Bradyarrhythmias that impair cardiac output (Nagpal *et al.*, 2024). Arrhythmias are usually as a result of impaired impulse production or conduction, usually under structural, genetic, metabolic or electrophysiological anomalies of cardiac tissue. According to the modern reviews, the dysfunction of ion channels, fibrosis, inflammation, and autonomic imbalance represent the key factors that contribute to the development and persistence of arrhythmias (Okamoto and Tsumoto, 2024). Arrhythmias are a significant clinical issue in the whole world since they are the leading causes of morbidity, hospitalization and unexpected cardiac arrest. Atrial fibrillation is widespread constant irregular heartbeat and it is linked to stroke, and significant cardiovascular events (Kingma, Simard & Drolet, 2023).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Recent reviews have indicated that the growth in the elderly population, cardiovascular comorbidities, and lifestyle-related issues have contributed to the development of AF and ventricular arrhythmias at an accelerated rate across the world. Due to this, healthcare costs and clinical care associated with arrhythmia have increased significantly over the last few years (Crijns, 2022). The progress in the field of electrophysiology has enhanced our knowledge in the mechanisms of arrhythmia. Research on ion channelopathies such as Brugada syndrome, Long QT syndrome and arrhythmogenic cardiomyopathy has brought forward the role of genetic mutations and defective ion conductance in life-threatening arrhythmia (Leung *et al.*, 2023).

Arrhythmia diagnostics has developed at a high pace, and digital ECG devices, artificial-intelligence-powered prediction algorithms, and machine-learning classification systems have proven to be more accurate in rhythm recognition. They are commonly integrated into clinical and research practices in order to improve the early diagnosis (Silva *et al.*, 2025). Several reviews highlight the fact that antiarrhythmic medications are still significant, especially in rhythm-control methods of atrial fibrillation. Their use, however, should be closely monitored because of the possible pro-arrhythmic effect and systemic toxicity (Dye *et al.*, 2023). Arrhythmias emerged as a complication among patients admitted during the COVID-19 outbreak, linked to myocarditis, hypoxia, inflammation and medication interactions. This highlighted the significance of diseases, as potential contributors to arrhythmia (Wibaux *et al.*, 2023; PubMed 2022).

In general, the literature of the recent past highlights that the significance of early diagnostic, personalized therapy, and technology integration in the management of arrhythmia has increased. In the future, there will be individualized electrophysiology, genetic screening, and AI-based diagnostic systems to decrease mortality based on arrhythmias and enhance outcomes (Saber and Abotaleb, 2022; Gunawardhana *et al.*, 2024).

2. Understanding Normal Cardiac Passage System

The cardiac passage system starts and coordinates the electrical signals that make the atria and ventricles contract in a rhythmic and synchronized way. The sinoatrial node is where electrical impulses normally start. The sympathetic and parasympathetic nerves supply the SA node (Rachmat Hidayat, 2023). Rather, the SA nodal pacemaker activity should be deduced indirectly based on the P waves of the atrial activity. The rate and rhythm of the heart are susceptible to any sinus node dysfunction (Kashou AH *et al.*, 2022). The secondary pacemaker is found on the right interatrial septum over the valva tricuspidalis and before the coronary sinus ostium, which leads to action potentials being conducted into the ventricles. Out of the AV node, the fiber strands become unified to create the bundle of His (atrioventricular bundle) at the posterior border of the interventricular septum (John kingma, 2023).

Normal cardiac conduction system facilitates, not only, production of this impulse, but also, automatic transmission of the same to the entire atrial and ventricular myocardium that results in full contraction of the heart muscle (John Whitaker *et al.*, 2023).

3. Abnormal heart rhythm

Auscultation or palpating a patient's arterial pulse or precordium may reveal an irregular cardiac rhythm or unexpected heart rate (HR). Heart rhythm abnormalities are caused by a variety of reasons. When typically suppressed Purkinje cells become more active spontaneously and compete with the sinus node discharge, ectopic rhythms can also occur in the ventricle (Ware, Bonagura, & Scansen, 2021).

4. Classification of arrhythmias

The ECG is a non-invasive tool for diagnosing arrhythmia, which is caused by electrical system faults in the heart (Sun *et al.*, 2021). Electrocardiogram waveform-based data classification has advanced significantly thanks to deep learning. The goal of data science research over the last ten years has been to create artificial intelligence (AI)-based models that can precisely detect and categorize aberrant heart rhythms by analyzing ECG waveforms (Utkarsh Gupta *et al.*, 2024). Supraventricular, ventricular, and bradyarrhythmias are the three primary categories of cardiac arrhythmias. Each group has unique illnesses with varying causes, symptoms, and approaches to treatment (Anmol K Nagpal *et al.*, 2024).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

5. Supraventricular and Ventricular arrhythmias

5.1Supraventricular arrhythmias

Patients may have painful symptoms due to supraventricular arrhythmias. Since the primary care environment is frequently the first point of contact, it is crucial for the general small but significant signals to the diagnosis and first management. To give the patient the right treatment, it is crucial to comprehend the mechanisms underlying cardiac arrhythmias (DeSimone, Naksuk, & Asirvatham, 2018). While children's heart rates might range from 180 to 220 bpm, adults' heart rates surpass 100 bpm (Fig. 01).




Fig. 01: Abnormal heart beat due to supra ventricular arrhythmia at atrioventricular node

5.2Ventricular arrhythmias

An arrhythmia that arises from tissue underneath the penetrating AV bundle and causes a rapid (>100 beats per minute; bpm) ventricular rate is known as ventricular tachycardia (Fig. 02). Both the ventricular myocardium and specialized conducting tissue may cause or be involved in these arrhythmias (Whitaker, Wright & Tedrow, 2023). Prior to starting treatment, it is also necessary to comprehend the pathophysiology of heart rate variability. The start and spread of cardiac arrhythmias will occur differently in patients with and without structural heart disease (Francis Hartage *et al.*, 2024).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593




Fig. 02: Chaotic irregular wave formation due to ventricular fibrillation

6. Clinical Importance

In the general population, arrhythmias are predicted to be 1.5% to 5% common, with atrial fibrillation being the most prevalent. It might be challenging to determine the true prevalence of arrhythmias because they can be paroxysmal and exhibit no symptom (Desai & Hajoul, 2023). In the past, inflammation was thought to primarily as an aspect linked to arrhythmia; however, the recently identified inflammatory and irregular roles of cardiac immune cells suggest that leukocytes can cause arrhythmia by interacting with cardiac muscle cells or changing the composition of tissue (Grune, Yamazoe, & Nahrendorf, 2021).

Palpitations, lightheadedness, fainting, chest pain, dyspnea, exhaustion, and anxiety are just a few of the many symptoms that can accompany cardiac arrhythmias. It's crucial to remember, though, that some arrhythmias can be asymptomatic and go undetected; the abnormal heartbeat may be discovered accidentally during diagnostic testing for other illnesses or during a routine physical examination (Nagpal *et al.,* 2024). The most common type of arrhythmia is AF. Globally, 33.5 million persons had AF in 2010. The 2017 database shows that 3.046 million new cases of AF were reported worldwide (Gronthy *et al.,* 2023).

7. Atrial fibrillation

The most frequently observed arrhythmia in clinical practice is atrial fibrillation that is linked with an elevated risk of mortality, stroke and peripheral embolism. The study of the Global Burden of disease shows that there will be no less than 33.5 million AF patients (Sagris *et al.,* 2021). The AF prevalence in the world has radically grown by 33.5 million to 59 million people with AF in the 2010-19 (Linz *et al.,* 2024). Additional variables that have been noted as modifiable risk factors in the development of AF where structural and electrical remodeling of the atria has been established are an inactive lifestyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea and high blood pressure that facilitate AF (Bizhanov *et al.,* 2022). Atrial fibrillation is a common heart rhythm problem that affects the heart's upper chambers. In Paroxysmal atrial fibrillation, episodes begin suddenly and usually stop on their own within seven days. While in Permanent atrial fibrillation, the abnormal rhythm has been present for more than 12 months and requires ongoing, long-term care. Whereas, long standing Persistent atrial fibrillation, the irregular heartbeat lasts longer than seven days and often needs medical treatment to restore a normal rhythm (Fig. 03).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593




Fig. 03: Types of atrial fibrillation

8. Atrial flutter

After AF, AFL is the second most common disease. It is a large-scale rhythm that can be either independent (atypical) or dependent on the cavotricuspid isthmus that is typical (Kho *et al.*, 2022). Often coexists with atrial fibrillation in the same patient, even though it can occur as a stand-alone arrhythmia (T. Wybraniec *et al.*, 2023). Atrial flutter (AFL) increases the risk of heart failure, stroke, blood clot development, and cardiovascular mortality (Turek *et al.*, 2024). Electrocardiography is used to make the diagnosis. Medicine is used to control rate, anticoagulants are used to avoid blood clots, and medicine, cardiac arrest, or atrial flutter substrate surgery are frequently used to convert the patient to sinus rhythm (L. Brent Mitchell, 2024).

9. Ventricular tachycardia

Particularly in individuals with structural heart disease, ventricular tachycardia is a potentially fatal arrhythmia linked to a high morbidity-mortality rate (Smith *et al.*, 2024). Dr. Thomas Lewis initially reported VT in 1909 after noticing a sequence of ventricularly generated extra systole beats in a patient experiencing frequent episodes of palpitations and dyspnea (Hartage *et al.*, 2024). VT induction, as with other arrhythmias, has been the cornerstone of suppression for years. Four mapping techniques (entrainment, pace, activation, and substrate) have been proposed to tackle a range of problems and allow the best definition of the arrhythmia source (Cori et al., 2024).

10. Ventricular fibrillation

A serious and sometimes lethal arrhythmia, ventricular fibrillation necessitates prompt medical attention, typically in the form of defibrillation (Fira, Costin & Goras, 2024). Ventricular fibrillation in the context of acute myocardial ischemia is the primary cause of sudden cardiac mortality in the adult population (Warming *et al.*, 2025). Extended ventricular fibrillation leads to a reduction in the

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

amplitude of the waveform which is coarse VF at the beginning of the waveform and degenerates into asystole due to the gradual depletion of cardiac energy sources (Ed Burns & Robert Buttner, 2024). External electrical defibrillation remains the best treatment of VF. The heart is shocked to uniformly depolarize a uniformly large mass of the excitable myocardium and do so simultaneously (Keith A Marill, 2025).

11. Types of Heart Blockage

Bradycardia is when the heart beats slower than 50-60 beats per minute. It can happen in healthy young athletes or in older people, or those with certain medical conditions. Bradyarrhythmias happen when there's a problem in the heart's natural pacemaker, and other nodes. (Sidhu & Marine, 2020).Heart block happens when the electrical signals that control the heartbeat don't move properly from the top to the bottom of the heart. Electrical impulses normally travel from the atria to the ventricles. These signals pass through the AV node, which is a group of cells that connects the upper and lower parts of the heart (Friedman et al., 2003).Sinus node dysfunction is a form of heart block that develops within the sinus node, the region responsible for generating the hearts natural rhythm. The sinus node is a group of tissues (Hawks et al., 2021).Atrioventricular node block is heart block happens when the conduction through the AV node is delayed. The AV node contains specialized cells that regulates how electrical messages move from the arteria into the ventricle (Fumarulo et al., 2025).

First-degree blockage the electrical impulse moves slowly but still reaches the ventricles. This classification represents the mildest level of heart block. Second-degree heart block is develops when the electrical signals cannot consistently reach the lower chamber of the heart, which happens around 50% of times (Barold & Herweg, 2024).Third-degree heart block is also known as complete heart block, represents the most advanced and serious stage. It occurs when none of the electrical signals are able to pass between the upper chamber and the ventricles. This blockage stops the heart from beating correctly, which can decrease blood flow to the body. This condition usually needs a pacemaker to help manage the heartbeat (Meloy, Rutz & Bhambri, 2022).

12. Electrophysiological basis of Arrhythmias

Changes in the electrical activity of heart cells can lead to arrhythmias, which are irregular heartbeats. These changes affect the electrical signals inside heart cells. Certain electrical behaviors like automaticity, triggered activity, and reentry can cause arrhythmias. How these electrical changes affect the heart's electrical activity and the ECG (electrocardiogram) during an arrhythmia is explained in detail (Cabo & Wit, 1997).

13. Genetic factors:

Some genetic changes can cause arrhythmias. Mutations in genes that control ion channels, like SCN5A, KCNQ1, and KCNH2, can lead to conditions such as long QT syndrome, Brigades syndrome, and short QT disease pattern. Other genes involved in controlling calcium levels, such as RYR2 and CASQ2, can cause conditions like catecholaminergic polymorphic ventricular tachycardia. Mutations in structural protein genes like PKP2, DSP, FLNC, and others are linked to arrhythmogenic cardiomyopathies (Kim *et al.,* 2021). Ion channel gene mutations includes change in the SCN5A can cause Brugada disease or long QT syndrome by affecting the sodium channels in the heart. Mutations in the KCNQ1 and KCNH2 genes, which are potassium channel genes, are major causes of long QT syndrome (Jaegar *et al.,* 2021). Calcium regulation gene mutations are the mutations in the RYR2 and CASQ2 genes, which help control calcium in heart cells, can lead to CPVT, a condition with a high risk of dangerous arrhythmias (Schwarts *et al.,* 2020). Structural protein gene mutations are the mutations in desmosomal genes like PKP2, DSP, DSG2, C2, and TMSM43 are linked to ARVC, a condition that can cause serious arrhythmias. Mutations in genes for proteins such as lamina and flamin, like FLNC, can also increase the threat of VA and atrial fibrillation (Wilde & Bezzina, 2005).

14. Ion Channel Dysfunction:

Ion channels in heart muscle cells, especially those for sodium, potassium, and calcium, are very important for creating the normal electrical activity in the heart. These channels control how the heart muscle cells charge and discharge, which is needed for the heart to beat properly. These channels also

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

help with the contraction of the heart by controlling calcium levels (Guo & Zha, 2024). Problems with these ion channels can happen if there are genetic mutations or issues with how the genes that make these channels work. This can lead to a group of disorders called cardiac channelopathies (Abriel & Zaklyazminskaya, 2013). These conditions are usually inherited and include things like Symptoms that affect how the heart's electrical signals move. These problems often happen even when the heart's structure is normal (Hsio *et al.,* 2013). In long QT syndrome, changes in the genes that control potassium channels can reduce the flow of potassium out of the heart cells. This can also affect sodium or calcium channels, causing the heart cells to take longer to return to their normal state. This prolongation increases the risk of dangerous heart rhythms (Alfred & George, 2013).

15. Structural heart diseases:

In patients with the hereditary or acquired cardiomyopathies, pathogenic variants can affect not only iron channel brains but also structural proteins, leading both to mechanical dysfunction and arrhythmogenic remodeling (Marian *et al.,* 2020). After a myocardial injury for example myocardial infarction, scar tissue forms. This car can disrupt condition pathways, promote reentry circuits, and lead to ventricular tachycardia or ventricular fibrillation (Ventricular Tachycardia in Structural Heart Disease, 2020). Arrhythmia can happen to anyone, but some things might make it more likely to happen. Heart problems, not managing diabetes or high blood pressure well, thyroid issues, like an overactive thyroid, long-term lung problems, Eating badly and not being active enough, doing a lot of intense exercise, using too much caffeine, alcohol, or tobacco (Durrani, Fatima, & Shaikh, 2023).

16. Symptoms and Warning Signs:

Arrhythmias can cause many different symptoms and effects. The way someone feels when they have an arrhythmia depends on the type. If a premature beat happens often or in quick succession, a person might feel their heart race or have a fluttering feeling in their chest or neck. This is also what happens with atrial fibrillation (AFib or AF), a type of arrhythmia that causes a fluttering feeling. In some cases, acute or long-term heart failure can lead to more serious symptoms, such as sudden changes in heart rate or even fainting (Hsio *et al.,* 2013).

Feeling tired or weak, feeling dizzy or lightheaded, Fainting or almost fainting. A fast heartbeat or a fluttering feeling in the chest. Difficulty breathing and feelings of anxiety. Pain or pressure in the chest. Changes in heart rate, going from fast to slow. Sweating. The first step for patients with a serious illness, such as sudden collapse or loss of consciousness, is to go to an emergency department. The presence of a racing heart, dizziness, and lightheadedness are also reasons to seek immediate medical attention in the emergency room. This is not uncommon for these conditions.

Check for signs of heart palpitation that are not as common and less severe. If a family history of concern is present. A person may not have heart issues at this stage. The awareness of a family history can lead to screenings or treatment for those experiencing symptoms (Wilson, 2024).

17. Global Health Care Burden:

It includes the disease management organizations that how different parts of the world recognize, treat, and deal with heart rhythm problems. Arrhythmias can take many forms, such as atrial fibrillation, fast heart rhythms that can lead to sudden death, or slow heartbeats due to issues with the heart's natural pacemaker or the connections between the heart's chambers (American Heart Association, 2023). In poorer and middle income countries, people often face higher chances of dying from arrhythmias because of complicated risk factors, limited knowledge among healthcare workers, poor medical facilities, and difficulty in getting medical care. This is especially true in low and middle income countries, where these dangers are not well understood. To address these problems, several approaches are being explored, such as reusing pacemakers, setting up mobile clinics, using digital tools to improve training, and other methods (Garg *et al.,* 2024).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

18. Diagnostic approach by holter monitoring

A sensible diagnostic approach to suspected arrhythmia starts with a careful history that teases out when symptoms happen, what triggers them, and how they affect the person's daily life. A focused physical exam then looks for clues of structural heart disease or systemic contributors that could explain the rhythm problem. (Joglar et al., 2024). Because many rhythm disturbances are fleeting, a resting 12-lead ECG is essential but often must be paired with ambulatory monitoring, event recorders, or targeted imaging to actually catch an episode. Finally, clinicians use risk stratification considering symptom severity, comorbidities, and sudden death risk to decide between urgent treatment, outpatient monitoring, or more advanced testing. (Takase et al., 2024).

A Holter monitor gives a continuous ECG snapshot in commonly 24–48 hours, which makes it far than a single ECG to record short, symptomatic, or frequent intermittent arrhythmias. When events are less frequent, extending monitoring to 7–14 days or using implantable loop recorders markedly increases the chance of catching diagnostic events (Fabian, 2023). Choosing the correct device and duration is not trivial matching monitoring strategy to the symptom pattern measurably improves diagnostic yield and helps avoid unnecessary treatments. (2025 Holter diagnostic accuracy study, 2025).

19. Echocardiography and Wearable cardiac monitors

Echocardiography is our frontline imaging tool to see the heart's structure and function, and it often uncovers the substrate that predisposes someone to arrhythmia for example, chamber enlargement, valve disease, or reduced ventricular function. Advanced echo techniques such as strain imaging and 3-D assessments can detect subtler cardiomyopathies that basic measures miss, and these findings frequently change management (Thomas *et al.,* 2025). Combining echo with ECG and, when needed, CMR or CT provides a fuller, more actionable picture for therapy planning (ASE, 2025).Wearables from adhesive ECG patches to smartwatches using photo plethysmography (PPG) have dramatically widened our ability to detect paroxysmal or asymptomatic arrhythmias in everyday life (Janowski *et al.,* 2025). Different devices have different signal types, recording durations, and strengths, so clinicians must interpret results knowing each tool's limitations and false positive rates (Pandey *et al.,* 2025). While detection has increased, high quality evidence that wearable-driven detection reduces hard outcomes like stroke or death is still emerging, so clinicians should integrate wearable data thoughtfully into overall patient care (Barrera *et al.,* 2025).

20. Lifestyle and arrhythmia

Lifestyle matters: obesity, excess alcohol, poor sleep (including untreated sleep apnea), smoking, and inactivity all increase the chance of developing and of sustaining arrhythmias such as atrial fibrillation. Practical interventions (weight management, alcohol moderation, treating sleep apnea, and exercise programs) reduce AF burden and improve outcomes when combined with standard medical or procedural care (Yang *et al.,* 2023). Therefore, lifestyle modification should be presented to patient not as optional advice but as a concrete, evidence-based part of arrhythmia management (Chung *et al.,* 2020).

21. Pharmacological management

Drug therapy for arrhythmias spans rate control, rhythm control, anticoagulation when stroke risk is present, and treatments directed at underlying causes; choice depends on the arrhythmia type and patient comorbidities. Guidelines urge individualized therapy for example, preferring rate control in many older patients while reserving certain Class I or III agents for those without significant structural heart disease. Vigilant monitoring for proarrhythmia and drug interactions is essential whenever antiarrhythmic medications are used (King, 2024).

22. Beta-blockers & calcium channel blockers

Beta-blockers are often first-line for rate control because they blunt sympathetic tone and slow AV nodal conduction, helping both symptoms and hemodynamics in many tachyarrhythmia's (King, 2024). When beta-blockers are contraindicated or poorly tolerated, non-dihydropyridine calcium-channel blockers (verapamil or diltiazem) are effective alternatives for controlling ventricular rate in supraventricular tachycardias (Bruce, 2024).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

23. Catheter ablation

Catheter ablation works by precisely destroying tiny patches of heart tissue that are acting as the spark or the pathway for an arrhythmia, and for many people with symptomatic atrial fibrillation this can mean fewer episodes and a real improvement in daily life (Tzeis *et al.,* 2024). Contemporary guidelines support offering ablation sooner rather than later for selected patients who remain symptomatic despite or sometimes even before trying long-term drugs, provided the patient and clinician carefully weigh risks, benefits, and alternatives together (Joglar *et al.,* 2023).A pacemaker is a simple idea with big impact: when the heart's natural timing is too slow or unreliable, a small implanted device gently takes over the timing to prevent symptoms like dizziness and fainting (Shah *et al.,* 2021). In the last few years' clinicians have increasingly matched device type to the patient choosing single- or dual-chamber systems, MRI-conditional devices, or even leadless pacemakers to reduce complications and better fit people's lifestyles (Khan *et al.,* 2024).

24. (Implantable Cardioverter-Defibrillators)

ICDs (Fig. 04) are designed to be lifesaving. They monitor the heart and deliver a shock only when a dangerous ventricular rhythm threatens sudden death, so selecting the right candidate is a matter of balancing clear survival benefit against the device's burdens (Varga, 2024). Recent reviews and guideline updates stress optimizing medical therapy first, and then using careful risk assessment and shared decision-making especially in older or frail patients before committing to an implant (Leong *et al.,* 2024).




Fig. 04: Implantable Cardioverter-Defibrillators

25. Non-Invasive Treatments (including mapping)

Noninvasive electrical mapping techniques (often called ECGI) give a surface-based "map" of where abnormal rhythms likely begin, which helps plan procedures and sometimes avoids extra invasive mapping steps (Ballatore *et al.,* 2025). When ECGI results are combined with structural imaging like LGE-CMR, teams can better characterize scar-related ventricular substrates and target therapy more intelligently, although the technology is still being refined and validated across broader patient groups (Reventos Pressman's *et al.,* 2025).

26. Arrhythmias in different age groups

Children are not small adults: the kinds of arrhythmias you see, the way they present, and the long-term consequences differ across infancy, childhood and adolescence, so diagnosis and

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

treatment must be age appropriate and often multidisciplinary (Strangio *et al.*, 2025). Supraventricular tachycardia is the most common issue in pediatrics, and while many cases are managed conservatively or with short-term medication, modern catheter ablation offers a potential cure for selected children provided the team accounts for growth and future device needs (Cepeda-Nieto *et al.*, 2025).

Pregnancy creates a unique mix of hormones, fluid shifts and increased cardiac workload that can either unmask an arrhythmia or make a preexisting rhythm problem flare, and care must balance maternal benefit with fetal safety (Joglar *et al.*, 2023). Expert consensus now recommends management by a multidisciplinary team, prefers drugs with better pregnancy safety records, and reserves invasive options like catheter ablation for cases where symptoms or hemodynamics demand it and timing and expertise minimize fetal risk (Albertini *et al.*, 2023).

Regular training causes predictable electrical and structural adaptations in the athlete's heart, but intense or prolonged exercise can sometimes reveal or accelerate pro-arrhythmic conditions in people who already carry a vulnerable substrate (Lampert *et al.*, 2024). Recent consensus emphasizes individualized screening, careful symptom-driven evaluation, and shared decision-making about return to play aiming to keep athletes active while minimizing risk (Finocchiaro *et al.*, 2024). In practice that means looking beyond a "good ECG" and considering family history, imaging, genetics, and the type of sport when making recommendations (Lampert *et al.*, 2024).

27. Post-MI (Myocardial Infarction) Arrhythmias

After a myocardial infarction the scar that forms in the heart creates electrical islands and slow pathways that can sustain dangerous ventricular arrhythmias, so prevention and timely recognition are critical (Ma *et al.*, 2025). Clinical strategies combine optimization of ischemic and heart-failure therapies, targeted electrophysiology assessment, and selective use of ablation or ICDs for those at persistent high risk (Villar-Valero *et al.*, 2025).




Fig. 05: Abnormal heart rhythmicity due to erratic impulses generated in the SA node

28. COVID-19 and Arrhythmias

COVID-19 taught clinicians that even a respiratory virus can produce real cardiac consequences. Arrhythmias during acute infection are common in hospitalized patients and some people go on to have delayed rhythm disturbances after recovery (Yu *et al.*, 2024).The drivers are multiple myocardial inflammation, autonomic imbalance, pro-thrombotic

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

states and metabolic disruption so monitoring and follow-up are sensible, especially in those with symptoms or preexisting heart disease (Blasi *et al.*, 2024).

29. Metabolic Disorders (and cardiac electrophysiology)

The heart experiences structural changes and electrical system alterations because of metabolic issues which include obesity and insulin resistance and diabetes that increase the chances of developing atrial fibrillation and other arrhythmias (Lopaschuk, 2021). The current medical understanding of AF now recognizes it as an "electro-metabolic" condition which requires patients to achieve weight reduction and blood sugar management and complete cardio metabolic profile treatment in addition to their traditional rhythm control treatments (Qin, 2024).

Research indicates that emotional stress creates disturbances in body autonomic control which leads to sympathetic dominance and increases heart rhythm instability (Nakashima et al., 2022). People who have atrial fibrillation identify stress as their individual heart rhythm trigger according to their personal accounts which match findings from population research indicating that AF episodes become more frequent when people experience stress (Sanchez et al., 2021). The heart's electrical stability becomes disrupted when people experience brief periods of strong emotional states or physical demands which cause their catecholamine levels to change quickly (Kim & Lee, 2023). The integration of stress management approaches including meditation and resilience training and structured lifestyle routines has become more common in arrhythmia treatment according to Lambert et al. 2020).

30. Diet and Heart Rhythm

Research indicates that eating whole foods while following Mediterranean-style dietary patterns helps people reduce their chances of developing atrial fibrillation and decreases the severity of the condition (Kassab et al., 2022). The current research shows that people who drink alcohol and sugary drinks frequently develop AF according to multiple studies which studied contemporary populations (Hall et al., 2023). Research shows that weight loss programs which include long-term lifestyle coaching help patients with AF symptoms most effectively especially for those who received ablation or cardio version procedures (Abed et al., 2021). Medical professionals now recommend patients should follow plant-based diets while they should reduce their alcohol consumption and sweetened drink intake to achieve improved heart rhythm results (D'Alessandro et al., 2020).

31. Complications of Antiarrhythmic Drugs

Rhythm control treatment with antiarrhythmic medications continues as a primary therapy but these drugs have two major drawbacks which include causing proarrhythmia and specific damage to body organs (Mann et al., 2021). The medication amiodarone provides effective treatment but it causes long-term damage to thyroid organs and lung tissue and liver cells which needs ongoing medical check-ups (Khan et al., 2020). The risk of adverse outcomes becomes more severe when patients receive multiple medications at once because their electrophysiological effects particularly QT prolongation tend to accumulate and intensify (Patel et al., 2022

32. Case Studies

The current medical literature demonstrates how arrhythmia management becomes challenging when patients develop multiple heart rhythm problems together with device system malfunctions (Rossi et al., 2023). The complete understanding of electrophysiology requires healthcare providers to perform ECG analysis together with imaging tests and extended monitoring and genetic testing according to Benson et al. (2023). 2021). Multiple studies demonstrate that post-COVID arrhythmias together with uncommon structural heart problems have introduced new triggers which doctors now need to consider during their diagnostic process (Hartley et al., 2022). The combination of these clinical reports enables healthcare providers to develop useful treatment approaches which subsequently generate research inquiries that result in advanced scientific investigations (Miller & Zhou, 2020).

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

33. Advances in Arrhythmia Research

Considerable progress has been achieved in the field of cartography, allowing to target arrhythmogenic area with accuracy during catheter ablation (Chen et al., 2023). At the biological level, recent genetic and molecular breakthroughs are revealing why some cardiomyopathies and channelopathies make patients vulnerable to lethal rhythms (Liang et al., 2021). The advent of wearable cardiac monitors has also changed the playing field, capturing silent or paroxysmal arrhythmias that otherwise would have remained undiagnosed (Oliver et al., 2022). Meanwhile, advances in targeted drug development, biologics, and computer-aided modeling are increasingly paving the way for personalized treatment plans (Rahman et al., 2020).

33.1. Pulsed-Field Ablation (PFA)

The focus of arrhythmia prevention is increasingly sh ifting towards managing modifiable risk factors befor e electrical instability arises.Managing obesity, high bl ood pressure, diabetes, and excessive alcohol intake i s crucial in preventing and slowing the progression of arrhythmias (Johnson et al., 2021). Combining lifest yle changes with suitable medications, catheter ablati on, or devicebased treatments often leads to better sy mptom management and improved longterm outco mes for patients (Harper et al., 2022).

Pulsfield ablation marks a major advancement in the approach to cardiac ablation. Unlike conventional m ethods that employ heat or freezing to eliminate abn ormal tissue, PFA utilizes short, highvoltage electrical pulses to interrupt malfunctioning electrical pathwa ys through a mechanism called electroporation. This method enables more precise targeting of arrhythmo genic heart tissue,

while preserving the surrounding structures. Conseq uently, the likelihood of complications affecting the esophagus, phrenic nerve, or nearby organs is signific antly lower than with traditional ablation techniques . These safety benefits have made PFA a more appeal ing choice.

34. Artificial Intelligence and Deep Learning in ECG-Based Arrhythmia Care

Progress in datadriven technologies has revolutionize d the interpretation of electrocardiograms inarrhyth mia management. Advanced analytical models are no w capable of detecting subtle ECG

patterns linked to atrialfibrillation and other rhythm disorders, even when the data is obtained from single lead or wearable devices. These tools are being invest igated to aid in early risk prediction, assist in ablatio n planning, identify recurrence following treatment, and improve procedural mapping. As these systems t ransition from research environments to routine clin ical practice, they demonstrate an increasing ability t o assist clinicians in making more accurate and timel y decisions, all while continuing to depend

on expert judgment to guide patient care. (S. R., Nuzzle, M., & Keck, K. H., 2023).

35. Recommendations

- Avoid stimulants like caffeine, energy drinks, nicotine, and drugs.
- Reduce stress with relaxation techniques like yoga, prayer, or meditation.
- Get 7–8 hours of quality sleep and treat sleep problems like sleep apnea.
- Control blood pressure, diabetes, and cholesterol with regular checkups.
- Stay hydrated and maintain a healthy balance of electrolytes (potassium and magnesium).
- Maintain a healthy body weight and avoid obesity.
- Avoid smoking and limit alcohol intake to protect heart rhythm.

36. Conclusion

The understanding of cardiac arrhythmias has changed dramatically over the last five years due to breakthroughs in cardiovascular research, which have moved the field away from a purely electrophysiological viewpoint and toward a more integrated, systems-based understanding of illness. Current research demonstrates that arrhythmias are dynamic clinical entities resulting from the interplay of genetic susceptibility, structural remodeling, metabolic imbalance, inflammation, and autonomic dysfunction rather than discrete electrical abnormalities. The significant variation in clinical presentation and therapy response seen among patient populations can be explained by its multifaceted nature.

The shortcomings of conventional, symptom-driven classification and treatment approaches are critically

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

highlighted by recent research. Pharmacological treatments and device-based interventions, like pacemakers and implanted cardioverter-defibrillators, are still essential to treatment, but proarrhythmic risks, device-related issues, and insufficient targeting of underlying disease mechanisms frequently limit their efficacy. Recent results over the past five years indicate that altering the biological substrate that maintains arrhythmic episodes is more important for long-term rhythm regulation and mortality reduction than merely suppressing them. This change is most noticeable in research that links the persistence and recurrence of arrhythmias to atrial fibrosis, ventricular scar load, systemic inflammation, and ion-channel remodeling. The increasing significance of precision and personalized medicine is another important finding from recent studies. Advanced cardiac imaging, artificial intelligence-assisted rhythm analysis, and genetic profiling have all shown promise for enhancing risk assessment and directing tailored treatment. The literature does, however, also highlight a significant translational gap: many technologically promising techniques are still underutilized in ordinary clinical practice, particularly in countries with low and middle incomes. This discrepancy highlights the need for future advancements in arrhythmia care to strike a balance between innovation, accessibility, affordability, and clinical feasibility.

In summary, the available data suggests that cardiac arrhythmias are not episodic electrical disorders but rather persistent, complex diseases. An integrated management strategy that incorporates early identification, substrate change, lifestyle intervention, and prudent use of sophisticated therapeutics will be necessary for long-term improvements in patient outcomes. The crucial task that lies ahead is not just improving current technologies but also coordinating scientific discoveries with practical clinical application. In order to translate recent scientific advancements into significant decreases in arrhythmia-related morbidity and mortality, it will be imperative to address this obstacle.

REFERENCES

Abriel, H., & Zaklyazminskaya, E. V. (2013). Cardiac channelopathies: genetic and molecular mechanisms. *Gene*, *517*(1), 1-11.

Aimo, A., Milandri, A., Barison, A., Pezzato, A., Morfino, P., Vergaro, G. ... & Rapezzi, C. (2024). Electrocardiographic abnormalities in patients with cardiomyopathies. *Heart Failure Reviews*, *29*(1), 151-164.

Aksu, T., Brignole, M., Calo, L., Debruyne, P., Di Biase, L., Deharo, J. C. ... & Acosta, J. C. Z. (2024). Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: a scientific statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart Rhythm Society (LAHRS). *Europace*, *26*(8), euae206.

Ballatore, A., Saglietto, A., Cavallone, E., De Ferrari, G. M., Anselmino, M., & Dusi, V. (2025). Noninvasive Cardiac Electrical Activity Mapping Systems: Current Available Options. *Reviews in Cardiovascular Medicine*, *26*(11), 44335.

Bizhanov, K. A., Abzaliyev, K. B., Baimbetov, A. K., Sarsenbayeva, A. B., & Lyan, E. (2023). Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review). *Journal of cardiovascular electrophysiology*, *34*(1), 153-165.

Blasi, F., Vicenzi, M., & De Ponti, R. (2024). COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas. *Journal of Clinical Medicine*, *13*(23), 7259.

Cabo, C., & Wit, A. L. (1997). Cellular electrophysiologic mechanisms of cardiac arrhythmias. *Cardiology clinics*, *15*(4), 517-538.

Carnagarin, R., Kiuchi, M. G., Ho, J. K., Matthews, V. B., & Schlaich, M. P. (2019). Sympathetic nervous system activation and its modulation: role in atrial fibrillation. *Frontiers in neuroscience*, *12*, 1058.

Carter, C., Khan, Z., El-Zein, R., Lockhart, M., Shah, A., Newer, D., ... & Chopra, N. (2023). International Journal of Arrhythmia.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Ceren, İ. (2025). of Autonomic Dysfunction and Clinical Prognosis. *Heart Rate Variability-Current Practices and Clinical Applications: Current Practices and Clinical Applications*, 25.

Chan, A., Cohen, R., Robinson, K. M., Bhardwaj, D., Gregson, G., Jutai, J. W., ... & Fekr, A. R. (2022). Evidence and user considerations of home health monitoring for older adults: scoping review. *JMIR aging*, *5*(4), e40079.

Chang, M. (2022). *Atrial Fibrillation in Aging: Mechanisms and Potential Therapeutics* (Doctoral dissertation, University of South Florida).

Cheng, P., Xi, Y., Zou, Y., & Li, Z. (2025). Self-powered cardiovascular medical devices: From monitoring to therapy. *Cardiac Research*, *1*(1), 7-26.

Chmiel, J., & Kurpas, D. (2025). Neural Correlates of Restless Legs Syndrome (RLS) Based on Electroencephalogram (EEG)—A Mechanistic Review. *International Journal of Molecular Sciences*, *26*(21), 10675.

Coleman, J. A. (2024). *Investigations of electrophysiological mechanisms related to myocardial ischaemia in hypertrophic cardiomyopathy: implications for arrhythmic risk, ECG diagnosis, and antiarrhythmic therapy* (Doctoral dissertation, University of Oxford).

Crijns, H. J., Sanders, P., Albert, C. M., & Lambaste, P. D. (2022). The year in cardiovascular medicine 2021: arrhythmias. *European heart journal*, *43*(12), 1191-1197.

Desai, D. S., & Hajouli, S. (2023). Arrhythmias.[Updated 2022 Jun 11]. *StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing*.

DeSimone, C. V., Naksuk, N., & Asirvatham, S. J. (2018, December). Supraventricular arrhythmias: Clinical framework and common scenarios for the internist. In *Mayo Clinic Proceedings* (Vol. 93, No. 12, pp. 1825-1841). Elsevier.

Di Cori, A., Pistelli, L., Parollo, M., Zaurino, N., Segreti, L., & Zucchelli, G. (2024). Approaching Ventricular Tachycardia Ablation in 2024: An Update on Mapping and Ablation Strategies, Timing, and Future Directions. *Journal of Clinical Medicine*, *13*(17), 5017.

Fabian, D., & Ahmed, I. (2023). Ambulatory ECG monitoring. In *StatPearls [Internet]*. StatPearls Publishing.

Fahimi, B., Beikmohammadi, S., & Rostami, P. (2024). Atrial Fibrillation and Lifestyle Modification: Charting New Courses for Cardiovascular Health.

Finocchiaro, G., Westaby, J., Sheppard, M. N., Papadakis, M., & Sharma, S. (2024). Sudden cardiac death in young athletes: JACC state-of-the-art review. *Journal of the American College of Cardiology*, *83*(2), 350-370.

García, G. (2018). *Juan Francisco* (Doctoral dissertation, Universidad Politécnica de Valencia).

Garg, K., Satti, D. I., Yadav, R., Brumfield, J., Akwanalo, C. O., Mesubi, O. O., ... & Spragg, D. (2024). Global health inequities in electrophysiology care: a state-of-the-art review. *JACC: Advances*, *3*(12_Part_2), 101387.

Gertz, Z. M., Raina, A., Saghy, L., Zado, E. S., Callans, D. J., Marchlinski, F. E., ... & Silvestry, F. E. (2011). Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. *Journal of the American College of Cardiology*, *58*(14), 1474-1481.

Grace, A. A., & Roden, D. M. (2012). Systems biology and cardiac arrhythmias. *The Lancet*, *380*(9852), 1498-1508.

Gronthy, U. U., Biswas, U., Tapu, S., Samad, M. A., & Nahid, A. A. (2023). A bibliometric analysis on arrhythmia detection and classification from 2005 to 2022. *Diagnostics*, *13*(10), 1732.

Grune, J., Yamazoe, M., & Nahrendorf, M. (2021). Electroimmunology and cardiac arrhythmia. *Nature reviews cardiology*, *18*(8), 547-564.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Guo, S., & Zha, L. (2024). Pathogenesis and Clinical Characteristics of Hereditary Arrhythmia Diseases. *Genes*, *15*(11), 1368.

Gupta, U., Paluru, N., Nankani, D., Kulkarni, K., & Awasthi, N. (2024). A comprehensive review on efficient artificial intelligence models for classification of abnormal cardiac rhythms using electrocardiograms. *Heliyon*, *10*(5).

Haksari, E. L. (2019). Historical perspectives. *Dryland Agriculture*, *20*(10), 27-38.

Hartge, F., Skeete, J., Pinedo, A., Zeleke, B., Khan, A., Mekritthikrai, R., & Dye, C. A. (2024). Multi-Faceted Approach to Ventricular Tachycardia: A Review of Management Strategies. *Pharmacoepidemiology*, *3*(3), 265-284.

Hidayat, R. (2023). Overview of the Cardiac Conduction System: A Narrative Literature Review. *Sriwijaya Journal of Internal Medicine*, *1*(1), 9-14.

Hawks, M. K., Paul, M. L., & Malu, O. O. (2021). Sinus node dysfunction. *American family physician*, *104*(2), 179-185.

Fumarulo, I., Salerno, E. N. M., De Prisco, A., Ravenna, S. E., Grimaldi, M. C., Burzotta, F., & Aspromonte, N. (2025). Atrioventricular Node Dysfunction in Heart Failure: New Horizons from Pathophysiology to Therapeutic Perspectives. *Journal of Cardiovascular Development and Disease*, *12*(8), 310.

Friedman, D. M., Duncanson, L. J., Glickstein, J., & Buyon, J. P. (2003). A review of congenital heart block. *Images in paediatric cardiology*, *5*(3), 36.

Barold, S. S., & Herweg, B. (2024). Mobitz type II second-degree atrioventricular block: a commonly overdiagnosed and misinterpreted arrhythmia. *Frontiers in Cardiovascular Medicine*, *11*, 1450705.

Meloy, P., Rutz, D., & Bhambri, A. (2022). 3rd-degree atrioventricular block. *Journal of Education & Teaching in Emergency Medicine*, *7*(2), O1.

Durrani, D., Fatima, R., & Shaikh, M. (2023). Risk factors and management strategies for atrial fibrillation. *IJS Global Health*, *6*(5), e0318.

Wilson, S. R. (2024). Cardiac Symptoms Are Warning Signs for Arrhythmias and Sudden Death in Patients With Sickle Cell Disease. *The Hematologist*, *21*(2), 409-420.

Hsiao, P. Y., Tien, H. C., Lo, C. P., Juang, J. M. J., Wang, Y. H., & Sung, R. J. (2013). Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies. *The application of clinical genetics*, 1-13.

Jæger, K. H., Wall, S., & Tveito, A. (2021). Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes. *PLoS computational biology*, *17*(2), e1008089.

Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., ... & Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, *83*(1), 109-279.

Joglar, J. A., Kapa, S., Saarel, E. V., Dubin, A. M., Gorenek, B., Hameed, A. B., ... & Zentner, D. (2023). 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. *Heart Rhythm*, *20*(10), e175-e264.

Kashou, A. H., Basit, H., & Chhabra, L. (2017). Physiology, sinoatrial node.

Khurshid, S., Friedman, S., Reeder, C., Di Achille, P., Diamant, N., Singh, P., ... & Lubitz, S. A. (2022). ECG-based deep learning and clinical risk factors to predict atrial fibrillation. *Circulation*, *145*(2), 122-133.

Kim, Y. G., Oh, S. K., Choi, H. Y., & Choi, J. I. (2021). Inherited arrhythmia syndrome predisposing to sudden cardiac death. *The Korean Journal of Internal Medicine*, *36*(3), 527.

King, G. S., Goyal, A., Grigorova, Y., Patel, P., & Hashmi, M. F. (2024). Antiarrhythmic medications. In *StatPearls [Internet]*. StatPearls Publishing.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Kingma, J., Simard, C., & Drolet, B. (2023). Overview of cardiac arrhythmias and treatment strategies. *Pharmaceuticals*, *16*(6), 844.

Ko, N. L. K., Sriramoju, A., Khetarpal, B. K., & Srivathsan, K. (2022). Atypical atrial flutter: review of mechanisms, advances in mapping and ablation outcomes. *Current opinion in cardiology*, *37*(1), 36-45.

Lampert, R., Chung, E. H., Ackerman, M. J., Arroyo, A. R., Darden, D., Deo, R., ... & Shah, M. J. (2024). 2024 HRS expert consensus statement on arrhythmias in the athlete: evaluation, treatment, and return to play. *Heart Rhythm*, *21*(10), e151-e252.

Lee, W. C., Fang, H. Y., Chen, H. C., Lin, Y. S., Chen, M. C., & Liu, P. Y. (2025). Atrial cardiomyopathy-associated arrhythmia and the impact of sirtuin signaling pathway: a narrative review. *Current Vascular Pharmacology*, *23*(5), 311-323.

Leszto, K., Frąk, W., Kurciński, S., Sinkowska, J., Skwira, S., Młynarska, E., ... & Franczyk, B. (2024). Associations of dietary and lifestyle components with atrial fibrillation. *Nutrients*, *16*(3), 456.

Liaquat, M. T., & Makaryus, A. N. (2023). Cardiac electrical and structural remodeling. In *StatPearls [Internet]*. StatPearls Publishing.

Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021). Cardiac energy metabolism in heart failure. *Circulation research*, *128*(10), 1487-1513.

Lopez, E. M., & Malhotra, R. (2019). Ventricular tachycardia in structural heart disease. *The Journal of innovations in cardiac rhythm management*, *10*(8), 3762.

Ma, H., & Xu, H. (2025). Diagnosis and treatment of post-acute myocardial infarction ventricular aneurysm: A review. *Medicine*, *104*(32), e43696.

Majeed, H., & Sattar, Y. (2021). Electrophysiologic study indications and evaluation.

Marian, A. J., Asatryan, B., & Wehrens, X. H. (2020). Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. *Cardiovascular research*, *116*(9), 1600-1619.

Motohashi, S., Katsuta, E., & Ban, D. (2025). Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review. *Bioengineering*, *12*(12), 1315.

Nagpal, A. K., Pundkar, A., Singh, A., & Gad Kari, C. (2024). Cardiac arrhythmias and their management: An in-depth review of current practices and emerging therapies. *Cureus*, *16*(8).

Nasoufidou, A., Bantidos, M. G., Fyntanidou, B., Kofos, C., Stachteas, P., Arvanitaki, A. ... & Karagiannidis, E. (2025). Cardioprotective Mechanisms of Beta-Blockers in Myocardial Ischemia and Reperfusion: From Molecular Targets to Clinical Implications. *International Journal of Molecular Sciences*, *26*(20), 9843.

Negru, A. G., Iovanovici, D. C., Lascu, A., Pescariu, A. S., Cismaru, G., Crişan, S. ... & Luca, C. T. (2025). A comprehensive review of a mechanism-based ventricular electrical storm management. *Journal of Clinical Medicine*, *14*(15), 5351.

Nguyen, T. A., Teo, A. K. J., Zhao, Y., Quelapio, M., Hill, J., Morishita, F. ... & Marks, G. B. (2024). Population-wide active case finding as a strategy to end TB. *The Lancet Regional Health–Western Pacific*, *46*.

Okamoto, Y., & Tsumoto, K. (2024). Cardiac Arrhythmia: Molecular Mechanisms and Therapeutic Strategies. *International Journal of Molecular Sciences*, *25*(24), 13253.

Oliva, A., Grassi, S., Pinchi, V., Cazzato, F., Coll, M., Alcalde, M. ... & Campuzano, O. (2022). Structural heart alterations in Brugada syndrome: is it really a channelopathy? A systematic review. *Journal of Clinical Medicine*, *11*(15), 4406.

Patti, L., Horenstein, M. S., & Ashurst, J. V. (2025). Supraventricular tachycardia. In *StatPearls [Internet]*. StatPearls Publishing.

Pellikka, P. A., Douglas, P. S., Miller, J. G., Abraham, T. P., Baumann, R., Buxton, D. B., ... & Zamani, S. (2013). American society of echocardiography cardiovascular technology and research summit: a roadmap for 2020. *Journal of the American Society of Echocardiography*, *26*(4), 325-338.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021). C-Phycocyanin-derived phycocyanobilin as a potential nutraceutical approach for major neurodegenerative disorders and COVID-19-induced damage to the nervous system. *Current neuropharmacology*, *19*(12), 2250-2275.

Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., ... & GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *Journal of the American college of cardiology*, *76*(25), 2982-3021.

Sagris, M., Vardas, E. P., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., & Tousoulis, D. (2021). Atrial fibrillation: pathogenesis, predisposing factors, and genetics. *International journal of molecular sciences*, *23*(1), 6.

Saha, S. A., Russo, A. M., Chung, M. K., Deering, T. F., Lakkireddy, D., & Gopinathannair, R. (2022). COVID-19 and cardiac arrhythmias: a contemporary review. *Current treatment options in cardiovascular medicine*, *24*(6), 87-107.

Sattar, Y., & Chhabra, L. (2023). Electrocardiogram. In *StatPearls [Internet]*. StatPearls Publishing.

Schwartz, P. J., Ackerman, M. J., Antzelevitch, C., Bezzina, C. R., Borggrefe, M., Cuneo, B. F., & Wilde, A. A. (2020). Inherited cardiac arrhythmias. *Nature reviews Disease primers*, *6*(1), 58.

Shah, B., Saidullah, S., & Niaz, M. A. (2021). Trends In Permanent Pacemakersâ€™ Implantation: Where Do We Stand? *Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University*, *17*(2), 201-205.

Sidhu, S., & Marine, J. E. (2020). Evaluating and managing bradycardia. *Trends in cardiovascular medicine*, *30*(5), 265-272.

Stavrakis, S., Kulkarni, K., Singh, J. P., Katritsis, D. G., & Armoundas, A. A. (2020). Autonomic modulation of cardiac arrhythmias: methods to assess treatment and outcomes. *Clinical Electrophysiology*, *6*(5), 467-483.

Strangio, A., Ielapi, J., Sabatino, J., De Sarro, R., Di Costanzo, A., Sportelli, M. ... & Torella, D. (2025). Arrhythmias in Pediatric Age: A Narrative Review. *Children*, *12*(12), 1580.

Sun, H., Luo, D., Niu, X., Zeng, X., Zheng, B., Liu, H., & Pan, J. (2024). Classification algorithms in automatic diagnosis of ECG arrhythmias. *IEEE Access*.

Tamirisa, K. P., Oliveros, E., Paulraj, S., Mares, A. C., & Volgman, A. S. (2024). An overview of arrhythmias in pregnancy. *Methodist DeBakey Cardiovascular Journal*, *20*(2), 36.

Tisdale, J. E., Chung, M. K., Campbell, K. B., Hammadah, M., Joglar, J. A., Leclerc, J. ... & American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. (2020). Drug-induced arrhythmias: a scientific statement from the American Heart Association. *Circulation*, *142*(15), e214-e233.

Triposkiadis, F., Xanthopoulos, A., & Butler, J. (2019). Cardiovascular aging and heart failure: JACC review topic of the week. *Journal of the American College of Cardiology*, *74*(6), 804-813.

van Wijk, S. W., Su, W., Wijdeveld, L. F., Ramos, K. S., & Brundel, B. J. (2022). Cytoskeletal protein variants driving atrial fibrillation: potential mechanisms of action. *Cells*, *11*(3), 416.

Varga, C. R., Cleland, J. G., Abraham, W. T., Lip, G. Y., Leyva, F., & Hatamizadeh, P. (2024). Implantable cardioverter defibrillator and resynchronization therapy in patients with overt chronic kidney disease: JACC state-of-the-art review. *Journal of the American College of Cardiology*, *84*(14), 1342-1362.

Warming, P. E., Glinge, C., Dusi, V., Jabbari, R., Stampe, N. K., Tan, H. L., ... & ESCAPE-NET Investigators. (2025). Risk factors associated with ventricular fibrillation during first ST-elevation myocardial infarction: Individual participant data analysis of 3 prospective case-control studies. *Heart Rhythm*.

Wilde, A. A., & Bezzina, C. R. (2005). Genetics of cardiac arrhythmias. *Heart*, *91*(10), 1352-1358.

Frontier in Medical & Health Research

ISSN: (e) 3007-1607 (p) 3007-1593

Wybraniec, M. T., Gorny, K., Jabłoński, K., Jung, J., Rabtsevich, K., Szyszka, P. ... & Mizia-Stec, K. (2023). Clinical characteristics of atrial flutter and its response to pharmacological cardioversion with amiodarone in comparison to atrial fibrillation. *Journal of Clinical Medicine*, *12*(13), 4262.

Yang, L., & Chung, M. K. (2023). Lifestyle changes in atrial fibrillation management and intervention. *Journal of cardiovascular electrophysiology*, *34*(10), 2163-2178.

Yu, L., Liu, Y., & Feng, Y. (2024). Cardiac arrhythmia in COVID-19 patients. *Annals of noninvasive electrocardiology*, *29*(2), e13105.

Zeppenfeld, K., Tfelt-Hansen, J., De Riva, M., Winkel, B. G., Behr, E. R., Blom, N. A. ... & Volterrani, M. (2022). 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). *European heart journal*, *43*(40), 3997-4126.

Zhao, H. Y., Jiang, J. B., Wang, S. N., & Miao, C. Y. (2025). Cardiac Development, Cellular Composition and Function: From Regulatory Mechanisms to Applications. *Cells*, *14*(17), 1390.

Ziegler, K. A., Engelhardt, S., Carnevale, D., McAlpine, C. S., Guzik, T. J., Dimmeler, S., & Swirski, F. K. (2025). Neural mechanisms in cardiovascular health and disease. *Circulation Research*, *136*(11), 1233-1261.